A silk fibroin-based dissolvable microneedle for transdermal delivery of scorpion venom protein
Abstract: Background: Scorpion venom protein (SVP) possesses potent analgesic activity but requires daily intramuscular injection, severely compromising patient compliance. Transdermal delivery offers a painless alternative, yet the stratum corneum limits macromolecular permeation. Objectives: This study aimed to develop a silk fibroin (SF)-based dissolvable microneedle patch for transdermal delivery of SVP, enabling prolonged analgesic effect following a single administration. Methods: Dissolvable microneedles were fabricated using SF as a sustained-release matrix for needle tips and polyacrylic acid (PAA) as a soluble backing layer. Microneedles were characterized for morphology, mechanical strength, skin penetration ability and backing dissolution time. Skin irritation was assessed in male Sprague-Dawley (SD) rats. Analgesic efficacy was evaluated in male BALB/c mice using acetic acid-induced writhing and tail-flick assays, comparing the microneedle patch with intramuscular injection. Results: The fabricated microneedles were conical, ~590 μm in length, enabling effective penetration of mouse skin. The PAA backing dissolved completely within 5 min in phosphate-buffered saline (PBS). No skin irritation (erythema or edema) was observed. In the writhing test, the microneedle group showed inhibition rates of 74.0% at 1 h and 72.4% at 4 h; by contrast, the injection group showed 69.1% at 1 h but dropped sharply to 8.0% at 4 h. The tail-flick assay confirmed prolonged analgesia with microneedle application. Conclusion: SVP-loaded SF-based dissolvable microneedles are safe, provide sustained analgesic effects and represent a promising alternative to frequent injections for chronic pain management
Authors
- Xiaoyan Lu
Institutions
- Shandong College of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Pakistan Journal of Pharmaceutical Sciences
- Published
- 2026-11-15
- DOI
- https://doi.org/10.36721/pjps/2026.40.16763.1
- Primary Topic
- Advancements in Transdermal Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00